ClinicalTrials.gg
RecruitingNCT07057466AI-ECG-SHDUpdated Oct 8, 2026

Prospective Evaluation of AI-ECG for SHD Detection

An observational study in Valvular Heart Disease Stenosis and Regurgitation (Diagnosis), Pulmonary Hypertension (Diagnosis) and Heart Failure With Reduced Ejection Fraction (HFrEF; Diagnosis), sponsored by Imperial College London. Recruiting at 6 sites in United Kingdom. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Imperial College London · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 8, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
590
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies in Gastroesophageal Reflux with a site in United Kingdom — 5 open to participants now, 7 under way, 1 of them phase 3. Gastroesophageal Reflux · United Kingdom.

Planned enrollment
2nd of 19
590 · median 199
Started
2025
with 2 others
Observational
19 of 53
3 open now
Registered
50th of 53
by date
Lead sponsor
3 of 53
Imperial College London

Among the 53 studies in Gastroesophageal Reflux with a site in United Kingdom, this one is the 2nd largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2025, is one of 19 observational ones, and was the 50th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

5 of the 53 studies in Gastroesophageal Reflux with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Gastroesophageal Reflux with a site in United Kingdom, or all of them as a file.
02

Study summary

AI-ECG-SHD is a multicentre prospective observational diagnostic accuracy study evaluating artificial intelligence-enhanced electrocardiography (AI-ECG) for the detection of structural heart disease in adults undergoing clinically indicated transthoracic echocardiography (TTE).

Participants undergo standard 12-lead ECG acquisition together with ECG recordings obtained using portable or wearable single-, 3-, and 6-lead devices. Established AI-ECG models will be evaluated for the detection of heart failure, pulmonary hypertension and valvular heart disease using TTE as the clinical reference standard, with performance compared across ECG acquisition modalities within the same prospective cohort.

AI-ECG predictions are generated offline and are not provided to treating clinicians or used to alter clinical care. The study will also compare AI-ECG performance with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and evaluate the diagnostic performance of a combined AI-ECG and NT-proBNP approach.

The study aims to recruit 590 participants across six NHS hospital sites. A prespecified subgroup of 203 participants will undergo dedicated venous blood sampling for NT-proBNP; eligible same-day NT-proBNP measurements obtained as part of routine clinical care will also be included where available.

03

Conditions studied

  • Valvular Heart Disease Stenosis and Regurgitation (Diagnosis)
  • Pulmonary Hypertension (Diagnosis)
  • Heart Failure With Reduced Ejection Fraction (HFrEF; Diagnosis)
  • Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)

Keywords

  • Artificial Intelligence
  • Machine Learning
  • Wearable Devices
  • Portable Devices
  • Heart Failure
  • Pulmonary Hypertension
  • Valvular Heart Disease
  • Echocardiography
  • Electrocardiography
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This multicentre prospective observational diagnostic accuracy study will recruit 590 adult inpatients and outpatients aged 18-90 years undergoing transthoracic echocardiography (TTE) as part of routine clinical care.

Participants will be recruited from Chelsea and Westminster Hospital, West Middlesex University Hospital, Hammersmith Hospital, St Mary's Hospital, Bristol Royal Infirmary, and Southmead Hospital.

Patients with known severe structural heart disease are excluded. Patients with previously diagnosed structural abnormalities that do not meet the prespecified severe structural heart disease exclusion criteria may remain eligible for recruitment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients awaiting a transthoracic echocardiogram (TTE) based on clinical grounds as part of their standard care
  • Age 18-90 years
  • Able to provide

Exclusion criteria

Exclusion Criteria

  • Severe arrhythmia or unstable cardiovascular disease
  • Known severe structural heart disease, defined as any of the following: severe left ventricular systolic dysfunction ( ≤35%); severe valvular heart disease according to current British Society of Echocardiography criteria; high echocardiographic probability of pulmonary hypertension according to current British Society of Echocardiography criteria; or previous structural cardiac intervention, including valve repair, valve replacement/implantation, or surgical repair of a cardiac chamber or congenital structural abnormality
  • Cardiac implantable electronic device in situ, including a permanent pacemaker or implantable cardioverter defibrillator
  • Current or recent involvement in another research study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
590 participants (estimated)
Patient registry
No

Groups and cohorts

  • Echocardiography cohort

    Adult inpatients and outpatients undergoing transthoracic echocardiography (TTE) as part of routine clinical care will be recruited prospectively. Participants will undergo study-specific 12-lead ECG acquisition and portable or wearable single-, 3-, and 6-lead ECG recordings. Patients with known severe structural heart disease are excluded, while patients with previously diagnosed structural abnormalities that do not meet the prespecified severe structural heart disease exclusion criteria may remain eligible. AI-ECG predictions will be generated offline and will not inform clinical care.

    Other: Traditional 12-lead Electrocardiogram · Other: Apple Watch Series 4 Single-lead Electrocardiogram · Other: Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram · Other: AliveCor KardiaMobile Single- and 6-lead Electrocardiogram

  • N-terminal pro B-type natriuretic peptide subgroup

    A prespecified subgroup of 203 participants from the overall 590-participant cohort will be selected by stratified randomisation to undergo dedicated venepuncture for measurement of serum NT-proBNP. In addition, eligible same-day NT-proBNP measurements obtained as part of routine clinical care will be included in the NT-proBNP analysis where available. The final NT-proBNP analysis population may therefore exceed the dedicated 203-participant phlebotomy subgroup.

    Other: Traditional 12-lead Electrocardiogram · Other: Apple Watch Series 4 Single-lead Electrocardiogram · Other: Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram · Other: AliveCor KardiaMobile Single- and 6-lead Electrocardiogram · Other: Phlebotomy for N-terminal pro-B-type natriuretic peptide

Interventions

  • OtherTraditional 12-lead Electrocardiogram

    A study-specific standard 12-lead ECG recording will be obtained with the participant in a semi-reclined position. A 10-second ECG will be acquired and pseudonymised for subsequent offline AI-ECG analysis. AI-ECG outputs will not be used to inform or alter clinical care.

  • OtherApple Watch Series 4 Single-lead Electrocardiogram

    A 30-second single-lead ECG will be recorded using an Apple Watch Series 4. The watch will be worn on the participant's left wrist and the participant will place their right index finger on the Digital Crown during recording. The ECG will be used for subsequent offline AI-ECG analysis and will not inform clinical care.

  • OtherEko Core 500 Digital Stethoscope 3-lead Electrocardiogram

    A 30-second 3-lead ECG will be recorded using the Eko CORE 500 digital stethoscope with the participant seated. The device will be positioned over the upper left parasternal region. The ECG will be used for subsequent offline AI-ECG analysis and will not inform clinical care.

  • OtherAliveCor KardiaMobile Single- and 6-lead Electrocardiogram

    Two 30-second ECG recordings will be obtained using the AliveCor KardiaMobile 6L device: a single-lead recording with the participant's thumbs placed on the upper electrodes, followed by a 6-lead recording with the thumbs on the upper electrodes and the lower electrode in contact with the left knee or ankle. Recordings will be used for subsequent offline AI-ECG analysis and will not inform clinical care.

  • OtherPhlebotomy for N-terminal pro-B-type natriuretic peptide

    A single 10 mL venous blood sample will be collected from the prespecified subgroup of 203 participants for measurement of serum NT-proBNP. Samples will be analysed by the relevant hospital clinical biochemistry laboratory and disposed of after testing. Eligible same-day NT-proBNP measurements obtained as part of routine NHS care may also be included without an additional blood sample. NT-proBNP results collected for the study will not be used to alter clinical care.

06

What researchers measure

Primary outcomes

  1. AI-ECG model classification performance for detection of structural heart disease

    Diagnostic performance of the AI-ECG models for detection of heart failure (HF), pulmonary hypertension (PH), and valvular heart disease (VHD) will be evaluated separately across conventional 12-lead, derived single-lead, and device-acquired single-, 3-, and 6-lead ECG modalities. The primary measure of model discrimination will be the area under the receiver operating characteristic curve (AUROC).

    Time frame: Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.

Secondary outcomes

  1. Additional AI-ECG performance metrics for detection of structural heart disease

    Diagnostic performance will be evaluated separately for each AI-ECG model, disease phenotype, and ECG modality using the area under the precision-recall curve (AUPRC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and F1 score.

    Time frame: Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.

  2. Comparison of AI-ECG diagnostic performance across ECG modalities

    AI-ECG diagnostic performance will be compared across conventional 12-lead, derived single-lead, and device-acquired single-, 3-, and 6-lead ECG recordings obtained from the same participants. Comparisons will include AUROC and AUPRC, together with sensitivity, specificity, PPV, NPV, and F1 score, for each disease phenotype and ECG modality.

    Time frame: Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.

  3. NT-proBNP diagnostic performance for detection of structural heart disease

    The diagnostic performance of NT-proBNP for detection of HF, PH, and VHD will be evaluated against the same echocardiographic reference standards used for AI-ECG. Performance measures will include AUROC, AUPRC, sensitivity, specificity, PPV, NPV, and F1 score.

    Time frame: Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.

  4. Combined AI-ECG and NT-proBNP diagnostic performance

    AI-ECG predictions and NT-proBNP will be combined using logistic regression to evaluate the diagnostic performance of a combined digital and biochemical biomarker approach for detection of HF, PH, and VHD. Performance will be assessed using AUROC and AUPRC, with sensitivity, specificity, PPV, NPV, and F1 score also reported for binary model outputs.

    Time frame: Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 17 months after the start.

Of 95 non-industry observational studies under Gastroesophageal Reflux, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 167. This study's planned 17 months is below that.

Counting every sponsor, half of 117 studies reached it within 45 months; a quarter within 17 and three quarters within 134.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 9, 2025
StartActual
Nov 4, 2025
Primary completionEst.
May 3, 2027
CompletionEst.
Aug 2, 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Bristol Royal Infirmary · Bristol, United Kingdom
Oct 8, 2026
Eligibility
2 inclusion criteria edited, 1 added, 1 removed; 2 exclusion criteria edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • AddedPatients awaiting a transthoracic echocardiogram (TTE) based on clinical grounds as part of their standard care
  • EditedPatients agedAge 18-90 years
  • RemovedNo prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD
  • EditedAbilityAble to provide informed consent
Exclusion criteria
  • RemovedPrior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD
  • AddedKnown severe structural heart disease, defined as any of the following: severe left ventricular systolic dysfunction (LVEF ≤35%); severe valvular heart disease according to current British Society of Echocardiography criteria; high echocardiographic probability of pulmonary hypertension according to current British Society of Echocardiography criteria; or previous structural cardiac intervention, including valve repair, valve replacement/implantation, or surgical repair of a cardiac chamber or congenital structural abnormality
  • EditedCardiac implantable electronic device in- situ, including a permanent pacemaker or implantable cardioverter defibrillator
  • EditedInvolvement in current researchCurrent or recent involvement in anyanother research prior to recruitmentstudy
Oct 8, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedAI-ECG model classification performance for detection of structural heart disease (SHD)Time frame: From enrolment to end of patient's study visit (up to 1 hour) → Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
Oct 8, 2026
Secondary outcomes
3 edited, 1 added
What changed in the outcomes
  • EditedAdditional AI-ECG performance metrics for detection of SHDstructural heart diseaseTime frame: From enrolment to end of patient's study visit (up to 1 hour) → Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
  • EditedNT-proBNP diagnostic performance metrics for detection of SHDstructural heart diseaseTime frame: From enrolment to end of patient's study visit (up to 1 hour) → Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
  • EditedCombined AI-ECG and NT-proBNP diagnostic performance analysis for detection of SHDTime frame: From enrolment to end of patient's study visit (up to 1 hour) → Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
  • AddedComparison of AI-ECG diagnostic performance across ECG modalitiesTime frame: Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    1 site added
    Show site
    • Bristol Royal Infirmary · Bristol, United Kingdom
    Eligibility 2 inclusion criteria edited, 1 added, 1 removed; 2 exclusion criteria edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • AddedPatients awaiting a transthoracic echocardiogram (TTE) based on clinical grounds as part of their standard care
    • EditedPatients agedAge 18-90 years
    • RemovedNo prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD
    • EditedAbilityAble to provide informed consent
    Exclusion criteria
    • RemovedPrior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD
    • AddedKnown severe structural heart disease, defined as any of the following: severe left ventricular systolic dysfunction (LVEF ≤35%); severe valvular heart disease according to current British Society of Echocardiography criteria; high echocardiographic probability of pulmonary hypertension according to current British Society of Echocardiography criteria; or previous structural cardiac intervention, including valve repair, valve replacement/implantation, or surgical repair of a cardiac chamber or congenital structural abnormality
    • EditedCardiac implantable electronic device in- situ, including a permanent pacemaker or implantable cardioverter defibrillator
    • EditedInvolvement in current researchCurrent or recent involvement in anyanother research prior to recruitmentstudy
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedAI-ECG model classification performance for detection of structural heart disease (SHD)Time frame: From enrolment to end of patient's study visit (up to 1 hour) → Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
    Secondary outcomes 3 edited, 1 added
    What changed in the outcomes
    • EditedAdditional AI-ECG performance metrics for detection of SHDstructural heart diseaseTime frame: From enrolment to end of patient's study visit (up to 1 hour) → Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
    • EditedNT-proBNP diagnostic performance metrics for detection of SHDstructural heart diseaseTime frame: From enrolment to end of patient's study visit (up to 1 hour) → Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
    • EditedCombined AI-ECG and NT-proBNP diagnostic performance analysis for detection of SHDTime frame: From enrolment to end of patient's study visit (up to 1 hour) → Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
    • AddedComparison of AI-ECG diagnostic performance across ECG modalitiesTime frame: Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
    + 5 other changes: identifiers, verification date, description, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07057466
Responsible party
Sponsor
First posted
Jul 9, 2025
Start date
Nov 4, 2025
Primary completion
May 3, 2027 (estimated)
Completion
Aug 2, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Ahmed YM El-Medany, MBChB, MRCP, MSc, FHEA
Contact
a.el-medany24@imperial.ac.uk
+44 02075943614

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion